| Title: |
Acupoint Application with Tianjiu Powder for Pre-asthma: a Randomized Controlled Trial |
| Authors: |
GUO Xin; ZHOU Mingjuan; FAN Feiting; XIAO Jingmin; CHI Yihe; WU Lei; LIN Lin; CHEN Yuanbin |
| Source: |
Zhongguo quanke yixue, Vol 28, Iss 11, Pp 1367-1375 (2025) |
| Publisher Information: |
Chinese General Practice Publishing House Co., Ltd |
| Publication Year: |
2025 |
| Collection: |
Directory of Open Access Journals: DOAJ Articles |
| Subject Terms: |
bronchial asthma|external application of chinese medicine|acupoint application of chinese medicine|randomized controlled trial; Medicine |
| Description: |
Background Pre-asthma is a pre-disease state of asthma. However, effective interventions against pre-asthma at currently scant. Objective To assess the clinical efficacy and safety of acupoint application with Tianjiu Powder on treating pre-asthma, aiming to develop a traditional Chinese medicine (TCM) preventive therapy regimen for external treatment of pre-asthma. Methods This was a randomized, double-blind, placebo-parallel controlled trial. A total of 123 pre-asthma patients treated in the Guangdong Provincial Hospital of Chinese Medicine from August 1, 2016 to December 31, 2019 were recruited and randomly assigned into the treatment group (n=62) and control group (n=61) at a ratio of 1∶1. During the experimental period, 12 cases were dropped off in the treatment group and finally 50 patients who completed the experiments were involved in. In the control group, 38 cases were finally involved in after excluding 22 cases of drop-off and 1 with bronchiectasis. Acupoint application of Tianjiu Powder and placebo was respectively given to patients of the treatment group (n=50) and control group (n=38). After 24 weeks of treatment, patients were followed up for another 24 weeks. Primary and secondary outcomes before the treatment (V1 visit), at 12 weeks (V2 visit), 24 weeks (V3 visit) and 48 weeks of treatment (end of the follow-up, V4 visit) were compared between groups. The primary outcome was the negative conversion rate of the bronchial provocation test (BPT) /bronchial dilation test (BDT). Secondary outcomes included the positive rate of BPT/BDT, forced expiratory volume in one second (FEV1), small airway function indicators, TCM syndrome score, the 36-item Short-Form (SF-36) score, serum eosinophil cationic protein (ECP), eosinophil percentage (EOS%) and total serum immunoglobulin E (IgE). Adverse events were recorded during treatment. Results The negative conversion rate of BPT/BDT at V2 (66.1% vs. 47.5%), V3 (64.5% vs. 44.3%) and V4 (58.1% vs. 36.1%) was significantly higher in the treatment group than that ... |
| Document Type: |
article in journal/newspaper |
| Language: |
Chinese |
| Relation: |
https://www.chinagp.net/fileup/1007-9572/PDF/2024-020474.pdf; https://doaj.org/toc/1007-9572; https://doaj.org/article/6ccd4fa4dcca4fb6a825e56e455b6588 |
| DOI: |
10.12114/j.issn.1007-9572.2024.0044 |
| Availability: |
https://doi.org/10.12114/j.issn.1007-9572.2024.0044; https://doaj.org/article/6ccd4fa4dcca4fb6a825e56e455b6588 |
| Accession Number: |
edsbas.35FEA898 |
| Database: |
BASE |